Mary Anne Dunkin

August 02, 2009

As the number of biologic agents for rheumatoid arthritis (RA)-and rheumatologists’ use of these agents for RA and other rheumatological diseases-grows, getting coverage for RA treatment is taking an increasing investment of physicians’ staff time. However, the majority of respondents to a recent survey say it is an investment in patient care that is worth making.